Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects
Journal Title: Annals of Hepatology - Year 2011, Vol 10, Issue 3
Abstract
Introduction. CYP2D6 is a liver enzyme that metabolizes more that 25% of drugs and thus may play a pivotal role in drug-drug interactions. The promoter sequences of cytochrome P450 2D6 (CYP2D6) gene could impact metabolic activity. Methods. We analyzed genetic variations in the promoter sequence of CYP2D6 gene for 71 hepatitis C negative and 15 hepatitis C positive subjects. Results. We found two novel genetic variants -1822A→G; -1740C→T, only in two patients with hepatitis C. Also, two linked new promoter sequence variations at –2060 G→A and –2053 T→G nucleotide positions that present in both hepatitis C negative and positive subjects are identified. The -2060 and -2053 variations are confirmed to be in linkage disequilibrium. The individuals with -2060A/A, and -2053G/G variation appeared to be associated with significantly lower levels of liver CYP2D6 mRNA. Analysis of CYP2D6 enzymatic activity in *1/*1 (wild type) subjects revealed that hepatitis C positive subjects expressed about 2.6-fold lower activity (24.0 ± 1.5 vs. 62.6 ± 3.7 pmol/min/mg; p = 0.0061) relative to hepatitis C negative. Conclusion. These data suggest that promoter variations -1822A→G and -1740C→T are present only in hepatitis C infected subjects. Hepatitis C positive individuals were associated with a lower liver CYP2D6 enzyme activity.This work was supported in part by National Institutes of Health Grants GM 62883, GM 32165, AI52663, AI 077390, HL 56548. RJYH was also supported by Milo Gibaldi Endowment. KVK was supported in part by NIH grant DK-02957
Authors and Affiliations
Martin T. Ho, Edward J. Kelly, Miklos Bodor, Tot Bui, Kris V. Kowdley, Rodney J. Y. Ho
Keywords
Related Articles
- EP ID EP78049
- DOI -
- Views 93
- Downloads 0
Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma
Background and rationale of the study. Effect of Long-term nucleoside/nucleotide (NUC) on hepatocellular carcinoma (HCC) incidence in a population of HBeAg-negative genotype D patients has not been adequately studied in...
The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population
Background. Nonalcoholic fatty liver disease (NAFLD) encompasses: fatty liver (SS), steatohepatitis (NASH) with or without fibrosis and cirrhosis. Patatine-like phosphatas in domain 3 (PNPLA3; adiponutrin; SNP rs738409 C...
Hepatic portal venous gas
Antiviral therapy in patients with HCV-cirrhosis
The main cause of liver cirrhosis and liver cancer in the western world is Hepatitis C virus (HCV) infection. Liver transplantation is the only effective treatment once the disease is decompensated. In viremic patients w...
Long-delayed gross hematuria due to portal hypertension in an alcoholic cirrhotic patient with ileal conduit urinary diversion
Bleeding varices at the stomal site is an uncommon complication of ileal conduit urinary diversion in patients with portal hypertension. We describe a case with the longest delay reported in the literature, involving the...